That's up from 9% a year ago, and coverage fell to 53% from 57%. 24/7 Wall St. looks at what cash pricing means for Lilly and Novo ahead of earnings.
Recap by typeshit. Full story at 24/7 Wall St..
GEN ranks the best-selling drugs by 2025 sales, and Lilly's weight loss shot outpaced names like Merck's Keytruda on growth.
A Dongguk University family medicine professor calls gallbladder risk the real concern and says some Koreans fly to Japan, where the drugs reportedly cost about a third.
Ricks describes working with the Trump administration to lower obesity drug costs for older Americans, on the day Lilly posted third-quarter earnings.
Walmart and Bank of America are expanding coverage, while 10% of surveyed employers say they may drop it in 2027. Workers explain what coverage means for their budgets.
STAT
STAT's Pharmalittle notes Catherine Hanaway says Lilly broke its promise on discounted drugs to hospitals, alongside new results for a Lilly weight loss drug.
Nadolsky calls retatrutide the most powerful medicine likely to be approved soon for weight and type 2 diabetes, in his view.
Loading…